Phase 2 Sickle Cell Disease Trial, Recruiting NCT05336201 Sponsor: University of Alabama at Birmingham Condition: Sickle Cell Disease
Back to Sickle Cell Disease

Phase 2 Sickle Cell Disease Trial, Recruiting

NCT05336201
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with sickle cell disease (any type/form)
  • You are currently receiving care and being monitored at Children's of Alabama Hospital
  • You are between 10 and 18 years old
  • You speak English

Who may not be able to join:

  • You have a history of seizures or a stroke that caused obvious symptoms or disability
  • You have a history of an intellectual disability or autism spectrum disorder
  • You are unable to have an MRI scan for any reason, such as having metal implants, a nerve stimulator device, or a fear of enclosed spaces (claustrophobia)
  • You are currently taking psychiatric or mood-related medications (such as antidepressants, antipsychotics, or similar drugs)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 2056382189

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 July 2022
Est. completion
30 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Transition Readiness; Transition Readiness

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov